# Vera Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vera-therapeutics

- Industry: Biotechnology
- Headquarters: South San Francisco, US
- Website: www.veratx.com
- Total disclosed funding: $80M
- Latest round: Series C (Jan 19, 2021)
- Investors on record: 9

## About

Based in California, US, and founded in 2016 by Marshall Fordyce, Vera Therapeutics, Inc., f.k.a Trucode Gene Repair, Inc. operates as a biotechnology company that develops novel therapeutics to develop new therapies. In January 2021, Vera Therapeutics, Inc. raised USD 80 million in a Series C funding led by Abingworth, with participation from Alexandria Venture Investments, Fidelity Investments, Longitude Capital, Octagon Capital Investments, Surveyor Capital, GV, Kleiner Perkins, and Sofinnova Ventures. The company has raised a total of USD 114 million in funding. In 2021, Vera Therapeutics was acquired by NeuBase Therapeutics Inc. In May 2021, Vera Therapeutics, Inc. raised USD 47.85 million in an IPO, selling 4.35 million shares at USD 11 per share. The company is trading on the Nasdaq Global Market under the ticker symbol VERA.

Vera Therapeutics provides clinical research and development for the treatment of immunological and inflammatory diseases to enable patients in the treatment of IgA nephropathy (IgAN), which is a rare autoimmune disease. In addition, the company also develops and commercializes atacicept in all indications from Merck KGaA, Darmstadt, Germany, a leading science, and technology company.

The company generates revenue by offering the developed therapies to pharmaceutical companies.

The company plans to use its proceeds from January 2021 funding to support the advancement of its lead clinical candidate, atacicept, a novel inhibitor of B cells and plasma cells, in patients with IgA nephropathy (IgAN). In addition, the company also plans to scale its manufacturing capabilities and expand the therapeutic pipeline in immunologic and inflammatory diseases.

## Funding rounds

- Series C, Jan 19, 2021, $80M — Abingworth, Kleiner Perkins, Sofinnova Investments, Alexandria Venture Investments, Longitude Capital, Fidelity Investments, GV, Surveyor Capital, Octagon Capital Advisors

## Investors

- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series C
- Kleiner Perkins (https://capitalatlas.ai/funds/kleiner-perkins) — Series C
- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series C
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series C
- Longitude Capital (https://capitalatlas.ai/funds/longitude-capital) — Series C
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series C
- GV (https://capitalatlas.ai/funds/gv) — Series C
- Surveyor Capital — Series C
- Octagon Capital Advisors (https://capitalatlas.ai/funds/octagon-capital-advisors) — Series C